drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Gene-modified autologous T cells expressing a chimeric antigen receptor targeting CD19 on malignant B cells; mediates cytotoxicity and cytokine release.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express a CD19-specific chimeric antigen receptor; upon binding CD19 on malignant B cells, the CAR provides activation and co-stimulatory signaling (e.g., CD3zeta with CD28/4-1BB), driving T-cell activation, expansion, cytokine release, and perforin/granzyme-mediated lysis of CD19+ cells.
drug_name
CD19-directed autologous CAR-T cells
nct_id_drug_ref
NCT06695013